Advertisement
Advertisement
TOPIC
 / company

BeOne

BeOne
The latest news and top stories on BeOne Medicines. Hong Kong-listed BeOne Medicines, formerly BeiGene, specialises in developing and selling innovative oncology products. Headquartered in Beijing China with global operations, they primarily serve cancer patients worldwide, addressing unmet medical needs. Notable for its rapid growth and pioneering advancements in immuno-oncology, the company's key products include the blood cancer drug zanubrutinib (Brukinsa) and the oncology drug tislelizumab (Tevimbra). BeOne Medicines anticipates significant net profit, reflecting its focus on transforming cancer treatment through cutting-edge research and global expansion.
China’s private sector

China’s biotech boom drives surge in home-grown innovative drug approvals

Domestic firms dominate China’s drug approvals amid jump in spending and out-licensing deals as regulator speeds path to market.

Hang Seng Index review to boost market capitalisation by 4.5%: analysts

videocam

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals

Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement